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Identification of distinct loci for de novo DNA
methylation by DNMT3A and DNMT3B during
mammalian development
Masaki Yagi1,11,12, Mio Kabata2,3,12, Akito Tanaka2, Tomoyo Ukai1, Sho Ohta1, Kazuhiko Nakabayashi4,
Masahito Shimizu3, Kenichiro Hata4, Alexander Meissner 5,6,7, Takuya Yamamoto 2,8,9,10✉ &
Yasuhiro Yamada 1,8✉
De novo establishment of DNA methylation is accomplished by DNMT3A and DNMT3B.
Here, we analyze de novo DNA methylation in mouse embryonic fibroblasts (2i-MEFs)
derived from DNA-hypomethylated 2i/L ES cells with genetic ablation of Dnmt3a or Dnmt3b.
We identify 355 and 333 uniquely unmethylated genes in Dnmt3a and Dnmt3b knockout (KO)
2i-MEFs, respectively. We find that Dnmt3a is exclusively required for de novo methylation at
both TSS regions and gene bodies of Polycomb group (PcG) target developmental genes,
while Dnmt3b has a dominant role on the X chromosome. Consistent with this, tissue-specific
DNA methylation at PcG target genes is substantially reduced in Dnmt3a KO embryos.
Finally, we find that human patients with DNMT3mutations exhibit reduced DNA methylation
at regions that are hypomethylated in Dnmt3 KO 2i-MEFs. In conclusion, here we report a set
of unique de novo DNA methylation target sites for both DNMT3 enzymes during mam-
malian development that overlap with hypomethylated sites in human patients.
https://doi.org/10.1038/s41467-020-16989-w OPEN
1 Division of Stem Cell Pathology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639,
Japan. 2 Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan. 3 Department
of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan. 4Department of Maternal-Fetal Biology, National
Research Institute for Child Health and Development, Tokyo 157-8535, Japan. 5 Department of Genome Regulation, Max Planck Institute for Molecular
Genetics, Berlin, 14195, Germany. 6 Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA. 7 Broad Institute of
MIT and Harvard, Cambridge, MA, 02142, USA. 8 AMED-CREST, AMED 1-7-1 Otemachi, Tokyo 100-0004, Japan. 9 Institute for the Advanced Study of
Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan. 10Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced
Intelligence Project (AIP), Kyoto 606-8507, Japan. 11Present address: Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
02114, USA. 12These authors contributed equally: Masaki Yagi, Mio Kabata. ✉email: takuya@cira.kyoto-u.ac.jp; yasu@ims.u-tokyo.ac.jp









DNA methylation plays critical roles during mammaliandevelopment and ensures stable gene repression, genomicintegrity, X chromosome inactivation (XCI), and pre-
servation of genomic imprinting1–3. Three conserved DNA
methyltransferases, DNMT3A, DNMT3B, and DNMT1, are
responsible for de novo establishment and maintenance of DNA
methylation patterns4. The significance of DNA methyl-
transferases for mammalian development is highlighted by the
fact that genetic deletions of any of these enzymes have lethal
phenotypes in mice5,6. Moreover, dysregulation of DNMTs is
linked to several human diseases, including acute myeloid leu-
kemia (AML) and immunodeficiency, centromere instability, and
facial anomalies (ICF) syndrome, indicating that DNA methyl-
transferases are essential for normal mammalian development
and proper maintenance of somatic cells7,8.
Previous studies revealed the epigenetic mechanisms that
establish the strict methylome integrity required for normal
development. After epigenetic reprogramming in pre-
implantation embryos, the DNA methyltransferases DNMT3A
and DNMT3B, in conjunction with their nonenzymatic cofactor
DNMT3L, mediate global de novo DNA methylation during
embryonic and extraembryonic development5,9,10. DNMT3A and
DNMT3L establish genomic imprinting in gametes11–13, whereas
DNMT3B and DNMT3L are required for unique DNA methy-
lation patterns in placental progenitors10. The genomic enrich-
ment patterns of DNMT3A differ from those of DNMT3B in
mouse embryonic stem (ES) cells, suggesting that each de novo
methyltransferase has unique targets during development14,15.
Indeed, individual genetic ablation of these methyltransferases
results in lethal phenotypes at different developmental stages5.
However, it remains unclear whether the differential targeting of
DNMT3 enzymes is responsible for locus-specific de novo DNA
methylation during embryonic development.
To comprehensively identify the target sites for de novo DNA
methylation by the DNMT3 enzymes, in the present study, we
took advantage of female mouse ES cells established in the pre-
sence of MEK and Gsk3 inhibitors, which lack most DNA
methylation (2i/L ES cells)16. In combination with genetic abla-
tion of Dnmt3a or Dnmt3b, here we report unique de novo DNA
methylation target sites for both DNMT3 enzymes during
embryonic development.
Results
DNA hypomethylated ESCs for de novo methylation analysis.
Given the early embryonic lethal phenotype of Dnmt3b knockout
(KO) mice, ES cells could be a powerful tool for tracking and
comparing the de novo methylation activity of DNMT3s during
embryonic development (Fig. 1a). It should be noted, however,
that mouse ES cells cultured in serum and leukemia inhibitory
factor (LIF) (S/L ES cells) exhibit global DNA hypermethylation
relative to inner cell mass (ICM) cells, which are the in vivo
counterpart of ES cells17. Indeed, de novo methylated regions at
post-implantation epiblasts in vivo are already methylated in S/L
ES cells (Fig. 1b, c). Moreover, Polycomb group (PcG) target
transcription factor genes, which often include key developmental
genes, are highly methylated in S/L ES cells, but still hypo-
methylated in both ICM and epiblast (Fig. 1d and Supplementary
Fig. 1a), precluding the use of S/L ES cells for analysis of de novo
methylation at early developmental stages. In a previous study, we
showed that mouse ES cells established under 2i/L (MEK inhi-
bitor, Gsk3 inhibitor, and LIF) culture conditions (2i/L ES cells)
exhibit a substantial reduction in global DNA methylation levels16.
Female 2i/L ES cells lack DNA methylation at most sites, including
the PcG target genes (Fig. 1b–d and Supplementary Fig. 1a).
Collectively, these findings indicated that hypomethylated female
2i/L ES cells represent a powerful tool for de novo methylation
during early embryonic development.
In this study, to identify the unique targets of de novo
methylation by the DNMT3 enzymes, we used female mouse 2i/L
ES cells with targeted deletions in either Dnmt3a or Dnmt3b
(Fig. 1a). Dnmt3 KO 2i/L ES cells grow well and are
morphologically normal under 2i/L culture conditions16. In
addition, they efficiently contribute to chimeric embryos as
efficiently as wild-type (WT) 2i/L ES cells, indicating that Dnmt3
KO 2i/L ES cells retain pluripotency and the ability to
differentiate into somatic cells in vivo16. To compare the targets
of each DNA methyltransferase, we established mouse embryonic
fibroblasts (MEFs) from chimeric mice derived from female
Dnmt3 KO 2i/L ES cells (Dnmt3 KO 2i-MEFs), followed by
antibiotic selection, and assessed DNA methylation profiles by
whole-genome bisulfite sequencing (WGBS) and target-captured
MethylC-seq analysis (Supplementary Fig. 1b). Considering that
the 5 hmC level is negligible in ESCs18, we regarded both 5 hmC
and 5 mC as 5 mC in this study.
CpG methylation on all chromosomes was lower in both
Dnmt3a and Dnmt3b KO 2i-MEFs than in WT 2i-MEFs (Fig. 1e
and Supplementary Fig. 1c). Extending the analysis to various
genomic features, including transposable elements, we found that
both Dnmt3a and Dnmt3b KO decreased DNA methylation levels
on all elements (Fig. 1f, g). Consistent with a previous study19,
Dnmt3b KO 2i-MEFs exhibited a clear reduction in DNA
methylation on transposable elements relative to WT or Dnmt3a
KO 2i-MEFs (Fig. 1g). As shown in our previous study16, 2i-
MEFs exhibited global loss of genomic imprinting regardless of
Dnmt3 status (Supplementary Fig. 1d). When we divided all CpG
sites into three categories according to DNA methylation levels
[hypermethylated (>0.8), intermediate (0.2–0.8), and hypomethy-
lated (<0.2) sites], we found that hypermethylated CpG sites were
less abundant in Dnmt3b KO 2i-MEFs, whereas Dnmt3a KO 2i-
MEFs exhibited relatively modest reduction (Fig. 1h). The
reduced methylation level in Dnmt3b KO 2i-MEFs was observed
at regions marked by various histone marks, such as H3K36me3
and H3K9me3 (Supplementary Fig. 2a)14. We also found that
Dnmt3b KO epiblasts exhibit reduced CpG methylation levels at
de novo methylated regions during peri-implantation (from ICM
to post-implantation epiblasts) relative to WT or Dnmt3a KO
epiblasts (Supplementary Fig. 2b). Together, these results suggest
that DNMT3B de novo DNA methylation activity is predominant
in most genomic regions during early development.
Consistent with a previous report20, methylation levels at CGIs
on the X chromosome were markedly lower in Dnmt3b KO 2i-
MEFs than in Dnmt3a KO 2i-MEFs (Fig. 1i and Supplementary
Fig. 2c) (3a KO vs WT: p= 3.6 × 10−1, 3b KO vs WT: p= 1.2 ×
10−15; two-sided, Kolmogorov–Smirnov test), suggesting that
Dnmt3b is largely responsible for de novo CGI methylation on
the X chromosome. Non-CGI sites were also less methylated in
Dnmt3b KO 2i-MEFs, which was more pronounced on the X
chromosome than on autosomes (Fig. 1i and Supplementary
Fig. 2c–e) (3a KO vs WT: p < 2.2 × 10−16, 3b KO vs WT: p < 2.2 ×
10−16; two-sided, Kolmogorov–Smirnov test). In sharp contrast,
Dnmt3a KO 2i-MEFs did not exhibit an apparent reduction in
non-CGI methylation on the X chromosome (Fig. 1i and
Supplementary Fig. 2c). Collectively, these results suggest that
DNMT3B is the enzyme predominantly responsible for global de
novo methylation on the X chromosome during XCI.
Target genes of de novo methylation by DNMT3A and
DNMT3B. We next sought to identify, in an unbiased manner,
unique target loci of DNMT3A- and DNMT3B-mediated de novo
DNA methylation during embryonic development. To this end,
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we first identified differentially methylated tiles (DMT; non-
overlapping 1k tiles) that differed significantly between WT 2i-
MEFs and each KO 2i-MEFs by using WGBS data. Consistent
with previous reports5,21, DNA methylation levels at most regions
did not significantly differ between Dnmt3a and Dnmt3b KO 2i-
MEFs, but we identified thousands of DMTs in either of the KO
(4308 and 7357 DMTs in Dnmt3a and Dnmt3b KO 2i-MEFs,
respectively) (Fig. 2a and Supplementary Data 1). A small subset
of DMTs (n= 143) exhibited a modest reduction in DNA
methylation in both Dnmt3a KO and Dnmt3b KO 2i-MEFs,
suggesting that these loci are sufficiently methylated only when
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Supplementary Data 1). To uncover the specific target genes of
each methyltransferase, we used MethylC-seq data that are
enriched and have high coverage reads in gene regions. Notably,
we identified 355 and 333 specific target genes of DNMT3A and
DNMT3B, respectively (Fig. 2b, c and Supplementary Fig. 3a, b)
(Supplementary Data 2–5). Gene ontology (GO) analyses
revealed that DNMT3B-specific genes are involved in synapto-
nemal complex assembly (e.g., Tex12, Syde1, and Meioc), plasma
membrane (e.g., Pcdha/b family), and cell proliferation in fore-
brain (e.g., Wnt7a, Wnt7b, Wnt3a, and Zeb2) (Supplementary
Fig. 3c, and Supplementary Data 4 and 5). Our analysis identified
the previously reported DNMT3B-specific targets, Pcdha/b family
genes22, confirming that our strategy can successfully identify the
target genes of the de novo methyltransferase (Supplementary
Fig. 3a). By contrast, DNMT3A target genes included many
transcription factors that are essential for normal development,
including genes of the Hox, Gata, and Cbx families (Fig. 2c and
Supplementary Data 3 and 4). Consistent with this, GO analyses
indicated that DNMT3A target genes are involved in sequence-
specific DNA binding (e.g., Nr6a1, Gata2, Hoxc9, and Pou5f1),
transcription (e.g., Zfp46, Barx1, and Osr1), and pharyngeal sys-
tem development (e.g., Gata3, Six1, and Tbx1) (Supplementary
Fig. 3d). Because the DNMT3A target genes included many
developmental genes that are also known as PcG target tran-
scription factor genes23, we next hypothesized that DNMT3A
regulates de novo DNA methylation at PcG target developmental
genes during embryonic development. Notably, most of the PcG
target genes that acquire de novo DNA methylation during
embryonic development were strikingly hypomethylated in
Dnmt3a KO 2i-MEFs (Fig. 2d and Supplementary Fig. 3e) [3a KO
vs WT (mean methylation levels): p= 5.6 × 10−48, 3b KO vs WT
(mean methylation level): p= 8.2×10−16, Wilcoxon signed-rank
test]. For example, our data showed that all Hox gene clusters
(Hoxa, Hoxb, Hoxc, and Hoxd) located on different chromo-
somes, as well as other PcG target transcription factors, were
specifically methylated by DNMT3A (Fig. 2c, Supplementary
Fig. 3b, and Supplementary Data 3). The reduced DNA methy-
lation in Dnmt3a KO 2i-MEFs was observed in both short and
long genes (Supplementary Fig. 4a). To confirm DNMT3A-
mediated de novo methylation, we next examined the effect of
ectopic Dnmt3a expression on reduced methylation at PcG target
developmental genes in Dnmt3a KO cells. In these experiments,
we introduced a doxycycline (Dox)-inducible Dnmt3a1 expres-
sion vector into Dnmt3a KO 2i/L ES cells, and then differentiated
them into epiblast-like cells (EpiLCs) (Supplementary Fig. 4b).
Forced expression of Dnmt3a1 in Dnmt3a KO cells increased de
novo DNA methylation at Hoxa1 and Meis1 to a level similar to
that observed in WT cells (Supplementary Fig. 4c, d and Source
Data file). Based on these findings, we concluded that Dnmt3a
confers de novo DNA methylation at PcG target developmental
genes upon ES cell differentiation.
To more thoroughly examine DNMT3A-mediated de novo
methylation at PcG target developmental genes, we divided the
region of each PcG target gene into the Transcription Start Site
(TSS) region (TSS ± 1000 bp) and gene body [TSS to Transcrip-
tion End Site (TES)] and analyzed the methylation patterns
(Fig. 2e). The TSS regions of a subset of PcG target developmental
genes exhibited lower levels of de novo methylation in Dnmt3a
KO 2i-MEFs than in WT 2i-MEFs (Fig. 2e) [3a KO vs WT (mean
methylation levels, TSS): p < 2.2 × 10−16, 3b KO vs WT (mean
methylation levels, TSS): p= 5.4 × 10−14; two-sided, Wilcoxon
signed-rank test]. In contrast to the repressive role of DNA
methylation at TSS regions, gene body methylation is generally
associated with active transcription24. Consistent with this, gene
bodies of more highly expressed PcG target developmental genes
tended to have higher methylation levels in 2i-MEFs (Fig. 2e). In
addition, DNMT3B binds to gene bodies of actively transcribed
genes marked by H3K36me3, and is responsible for de novo DNA
methylation at the gene bodies14,25. Indeed, H3K36me3-marked
regions were less methylated in Dnmt3b KO 2i-MEFs than in
Dnmt3a KO 2i-MEFs (Supplementary Fig. 2a). Importantly,
however, gene bodies of PcG target genes were less methylated in
Dnmt3a KO 2i-MEFs than in Dnmt3b KO 2i-MEFs (Fig. 2e
and Supplementary Fig. 5a) [3a KO vs WT (Gene body): p < 2.2 ×
10−16, 3b KO vs WT (Gene body): p= 8.9 × 10−3; two-sided,
Wilcoxon signed-rank test]. The reduced methylation at gene
bodies in Dnmt3a KO 2i-MEFs was similarly observed at those
distant from TSS (Supplementary Fig. 5b), indicating that the
observed changes are not always associated with close proximity
of CpG islands linked to promoters. Collectively, these results
suggest that, in sharp contrast to other genes, gene bodies of PcG
target developmental genes are preferentially methylated by
DNMT3A, consistent with a recent study demonstrating that
DNMT3A1, a longer isoform of DNMT3A, preferentially
localizes to the methylated shores of bivalent CGIs in ES cells15.
Given that DNMT3A, together with DNMT3L, establishes
genomic imprinting in gametes, we examined the involvement
of DNMT3L in DNMT3A-mediated de novo methylation at PcG
target genes. However, methylation levels of PcG target genes
were comparable between Dnmt3l KO and WT E14.5 MEFs
(Supplementary Fig. 5c), demonstrating that DNMT3L is
dispensable for DNMT3A-mediated methylation at PcG target
genes during embryonic development.
Differential binding patterns of DNMT3A1 and DNMT3B1.
To obtain mechanistic insights into the locus specificity of
Fig. 1 DNA hypomethylated ES cells for de novo methylation analysis. a Schematic of experimental design. Either Dnmt3a or Dnmt3b was disrupted by
CRISPR/Cas9 in female 2i/L ES cells16. b CpG methylation levels at loci that were differentially methylated between ICM and epiblast (see the methods
section for details) in 2i/L ES cells and S/L ES cells. WGBS data were used for the analysis. White dots indicate median methylation levels. Black bars and
the lines stretched from the bar represent IQR and the lower/upper adjacent values (±1.5 IQR), respectively. ICM and epiblast data were obtained from
GSE8423610. Data of 2i/L ES cells, S/L ES cells, and 2i-MEFs are from GSE8416516. c CpG methylation levels at a representative genomic region including
the Hoxa cluster, as determined by WGBS. Each bar indicates a CpG site, and the height of the bar represents methylation percentage (0–100%). Locations
of genes and CpG islands (CGIs) are indicated below. Data are from GSE8423610 and GSE8416516. d CpG methylation levels at PcG target developmental
genes in ICM, epiblast, 2i/L ES cells, S/L ES cells, and 2i-MEFs, as determined by WGBS. Data were obtained from GSE8423610 and GSE8416516. e Relative
CpG methylation level [log2(fold change)] at each chromosome in Dnmt3 KO 2i-MEFs vs. wild-type 2i-MEFs, as determined by WGBS. Data from two
independent experiments are shown. f Relative CpG methylation levels [log2(fold change)] at CGIs, promoters [Transcription Start Site (TSS) ± 1000 bp],
exons, and introns in Dnmt3 KO 2i-MEFs vs. wild-type 2i-MEFs, as determined by MethylC-seq. g Relative CpG methylation levels [log2(fold change)] at
transposable elements (IAPs, LINEs, and SINEs) in Dnmt3 KO 2i-MEFs vs. wild-type 2i-MEFs by WGBS. h: Fraction of hypermethylated (>0.8), intermediate
(0.2–0.8), and hypomethylated (<0.2) CpG sites in wild-type and each type of KO 2i-MEFs. WGBS data (CpG sites at ≥5× coverage) were used for this
analysis. i CpG methylation levels at CGIs and non-CGIs on the X chromosome in WT, Dnmt3a KO, and Dnmt3b KO 2i-MEFs, as determined by WGBS.
White dots indicate median methylation levels.
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DNMT3 enzymes for de novo methylation, we examined geno-
mic enrichment patterns of DNMT3A and DNMT3B by ana-
lyzing ChIP-seq datasets14,15. Consistent with previous reports
demonstrating that DNMT3B is responsible for gene body
methylation of actively transcribed genes14,25, we confirmed
enrichment of DNMT3B1, but not DNMT3A1, in gene bodies
(Fig. 3a). Notably, DNMT3A, and especially DNMT3A1, was
enriched at DNMT3A target genes (Fig. 3a and Supplementary
Fig. 6a). By contrast, enrichment of DNMT3B1 was not altered at
target genes of DNMT3B-mediated de novo methylation
(Fig. 3a), suggesting the existence of distinct mechanisms gov-
erning the locus-specific activity of de novo methyltransferases.
Considering that DNMT3A mediates de novo methylation at PcG
target developmental genes, we next analyzed the binding pat-
terns of the DNMT3 enzymes on the PcG target genes. We
observed prominent enrichment of DNMT3A1 binding on PcG
target developmental genes, including enrichment in gene bodies
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PcG target genes23 (Fig. 3b), indicating that DNMT3B1 is pre-
cluded from these loci. Among DNMT3A target genes, further
enrichment of DNMT3A1 was observed on PcG target develop-
mental genes (Fig. 3c), and reduced binding of DNMT3B1 was
detected exclusively at DNMT3A target genes that were also PcG
target genes (Fig. 3c), highlighting unique binding patterns of
DNMT3 enzymes at PcG target loci. Together, these results
suggest that the preferred physical interactions of DNMT3A and
DNMT3B are associated with the locus-specific activity of the
enzymes at PcG target developmental genes.
Derepression of PcG target genes in Dnmt3a KO 2i-MEFs.
Given that DNA methylation at CGIs linked to TSS regions are
associated with gene repression, we next investigated the func-
tional implications of DNMT3-mediated de novo methylation on
gene expression during embryonic development. Because Dnmt3b
KO 2i-MEFs exhibited global CGI hypomethylation at the X
chromosome, we first performed RNA-seq analysis to compare
global gene expression profiles of X-linked genes between WT and
both types of Dnmt KO 2i-MEFs. Despite the significant reduction
in CGI methylation in Dnmt3b KO 2i-MEFs, expression levels of
X-linked genes were comparable among WT, Dnmt3a KO,
and Dnmt3b KO (3a KO: p= 7.6 × 10−1, 3b KO: p= 8.2 × 10−1)
(Fig. 4a), suggesting that DNA methylation–independent
mechanisms ensure dosage compensation of X-linked genes in
Dnmt3b KO 2i-MEFs26. We also examined expression of PcG
target developmental genes in WT and Dnmt KO 2i-MEFs.
Although reduced CGI methylation at PcG target developmental
genes was exclusively detectable in Dnmt3a KO 2i-MEFs,
expression levels of most PcG target developmental genes were not
altered in Dnmt3a KO 2i-MEFs (3a KO: p= 7.3 × 10−1, 3b KO: p
= 6.5 × 10−1) (Fig. 4b). However, when we focused on the TSS
regions of PcG target developmental genes expressed at low levels,
which were methylated in WT 2i-MEFs (>15%), we found that a
small subset of the PcG target genes (e.g., Pax8) was modestly
derepressed in Dnmt3a KO 2i-MEFs, accompanied by loss of
DNA methylation at TSS regions (Fig. 4c–e and Supplementary
Fig. 6b). To further investigate DNMT3A-mediated repression of
PcG target developmental genes, we also obtained MEFs from
Dnmt3a WT and null embryos by crossing Dnmt3a heterozygous
KO mice. Importantly, derepression of Pax8 was confirmed in
Dnmt3a KO MEFs (Supplementary Fig. 6c). Collectively, these
data indicate that DNMT3A-mediated DNA methylation plays a
role in stable silencing of a subset of PcG target developmental
genes.
Tissue-specific methylation at PcG target genes by DNMT3A.
Our previous study demonstrated that female 2i/L ES cells exhibit
a massive erasure of genomic imprints and harbor an impaired
autonomous developmental potential16, which raised the possi-
bility that the observed changes in DNA methylation are not
directly associated with DNMT3 de novo DNA methylation
activity. To investigate DNMT3A-mediated de novo methylation
during embryonic development in vivo, we obtained various tis-
sues (brain, limb, heart, lung, and liver) from Dnmt3a WT and
null embryos at E14.5 (Fig. 5a, b). We then performed MethylC-
seq analysis to compare DNA methylation patterns at PcG target
developmental genes in different tissues (Supplementary Fig. 1b).
Notably in this regard, PcG target genes in different tissues
exhibited distinct DNA methylation levels in WT embryos. For
example, the Hoxb cluster is methylated in the heart and liver, but
remains unmethylated in the brain (Fig. 5c). Notably, genetic
ablation of Dnmt3a resulted in a reduction in DNA methylation
at the Hoxb cluster in the heart and liver (Fig. 5c). Moreover,
other PcG target developmental genes such as Chromo, T-box,
and Hox families also exhibited tissue-specific methylation pat-
terns in WT organs, but were hypomethylated in Dnmt3a KO
tissues (Fig. 5d–e and Supplementary Fig. 7). Conventional
bisulfite sequencing analysis confirmed that the tissue-specific
methylation at Meis1 is mediated by DNMT3A (Supplementary
Fig. 8a). Consistent with the notion that PcG target develop-
mental genes are regulated by cooperative epigenetic mechan-
isms, most PcG target genes were expressed at similar levels in
WT and Dnmt3a KO tissues (Fig. 5f and Supplementary Fig. 8b).
Notably, gene bodies of transcriptionally active PcG target
developmental genes were highly methylated in both the heart
and liver, but were less methylated in Dnmt3a KO tissues (Sup-
plementary Fig. 8c), affirming that de novo methylation at gene
bodies of PcG target developmental genes is mediated by
DNMT3A in vivo. Taken together, these results underscore the
essential role of DNMT3A in establishing tissue-specific DNA
methylation patterns at PcG target developmental genes during
embryonic development.
Reduced DNA methylation in patients with DNMT3 muta-
tions. Finally, we investigated the unique functions of DNMT3A
and DNMT3B in humans. Somatic inactivating mutations of
DNMT3A and DNMT3B have been reported in AML27 and ICF
syndrome patients7, respectively. To investigate the possible
link between an impaired DNMT3 function and altered
DNA methylation in human diseases, we first analyzed DNA
methylation status at mouse DNMT3B target genes in ICF
patients harboring a DNMT3B mutation. Human homologs of a
subset of mouse DNMT3B target genes were similarly hypo-
methylated in DNMT3B mutant ICF patients relative to con-
trol patients (Fig. 6a). Importantly, in addition to the PCDH
family of genes, previously reported to be hypomethylated in
Fig. 2 Target genes of de novo methylation by DNMT3A and DNMT3B. a Heatmap of CpG methylation levels within 1 K tiled regions in which CpG
methylation levels differed between the WT and each Dnmt3 KO. Differentially methylated 1 K tiled regions are identified using the Bioconductor DSS
package with methylation status of nonoverlapping 1 K tiles that have ≥10 read coverages at CpG sites within a tile across all samples (see the methods
section in detail). b Representative loci of DNMT3B-specific target sites in 2i-MEFs. Each bar indicates a CpG site, and the height of the bar represents
methylation percentage, as determined by MethylC-seq (0–100%). Locations of genes and CGIs are indicated below. c Representative loci of DNMT3A-
specific target sites in 2i-MEFs. Essential developmental genes are frequently unmethylated in Dnmt3a KO 2i-MEFs. Each bar indicates a CpG site, and bar
height represents methylation percentage by MethylC-seq (0–100%). Locations of genes and CGIs are indicated below. d The left panel shows mean DNA
methylation levels at CpG sites within each PcG target developmental gene23 [from TSS to Transcription End Site (TES)] in WT 2i-MEFs from two
independent experiments. The right panel shows methylation difference between WT and each Dnmt3 KO 2i-MEFs from two independent experiments.
Genes are sorted by the mean methylation levels in the WT. Color scales indicate DNA methylation levels and their differences, respectively. e The upper
panel shows mean DNA methylation levels at CpG sites within TSS ± 1000 bp and gene body (TSS-TES) of each PcG target gene in WT 2i-MEFs from two
independent experiments. The lower panel shows methylation difference between WT and each type of Dnmt3 KO 2i-MEFs from two independent
experiments. Color scale indicates DNA methylation levels and their difference, respectively. PcG genes are ordered based on expression levels (FPKM
values) in WT 2i-MEFs (top panel).
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Fig. 3 Differential binding patterns of DNMT3A1 and DNMT3B1. a DNMT3A1 and DNMT3B1 binding to target genes for de novo methylation. ChIP-seq
data were obtained from GSE57413 and GSE9652914,15. Shading represents the standard error of the mean (SEM). b DNMT3A1 and DNMT3B1 binding to
PcG target developmental genes. Note that DNMT3A1 preferentially binds to PcG target genes, whereas DNMT3B1 is excluded from these genes. Shading
represents SEM. c DNMT3A1 and DNMT3B1 binding to DNMT3A target genes that are also PcG target genes. Further enrichment of DNMT3A1 was
observed on PcG target genes. Note that reduced binding of DNMT3B1 was exclusively detected at PcG target genes among DNMT3A target genes.
Shading represents SEM.
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ICF patients, we identified additional genes that were hypo-
methylated in both Dnmt3b KO 2i-MEFs and ICF patients (e.g.,
TMEM151A) (Fig. 6a,b). Taken together, our results provide
candidate genes that may be involved in the pathogenesis of ICF
syndrome.
We then examined the relationship between the DNMT3A
mutations and DNA methylation levels at PcG target develop-
mental genes in AML. Consistent with the assumption that
DNMT3A-inactivating mutations impair repression of PcG target
developmental genes, previous studies reported that some PcG
target developmental genes, such as HOX genes and MEIS1, are
dysregulated in AML and Dnmt3a null mouse hematopoietic
stem cells28–30. To explore this further, we examined a correlation
between the presence of the DNMT3A mutations and DNA
methylation levels at PcG target developmental genes in AML
using public datasets (GSE62298). Notably, among 30 differen-
tially methylated PcG target developmental genes, 29 (e.g.,
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Fig. 4 Derepression of PcG target genes in Dnmt3a KO 2i-MEFs. a Relative gene expression levels (FPKM+ 1) of X-linked genes (n= 320) in Dnmt3 KO
2i-MEFs (n= 1) vs. WT 2i-MEFs (n= 1), as determined by RNA-seq. Note that expression levels of most X-linked genes were comparable, regardless of
Dnmt3 status. Solid lines in each box indicate the median. The bottom and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to
±1.5 IQR. b Relative gene expression levels (FPKM+ 1) of PcG target developmental genes (n= 206) in Dnmt3 KO 2i-MEFs (n= 1) vs. WT 2i-MEFs (n= 1),
as determined by RNA-seq. Note that most PcG target genes were expressed at similar levels. Only a small subset of genes was modestly upregulated in
Dnmt3 KO 2i-MEFs. c Expression level (FPKM) of PcG target genes, as determined by RNA-seq. Genes methylated more than 15% at TSS ± 1000 bp in WT
2i-MEFs are shown. A small subset of genes was modestly derepressed in Dnmt3a KO 2i-MEFs relative to the other cell types. d qRT-PCR analysis for Pax8
in 2i-MEFs. Note that Pax8 was derepressed exclusively in Dnmt3a KO 2i-MEFs. Data are presented as means ± SD. The mean expression level of 2i-MEFs
was defined as 1. Statistical analysis was performed by Student’s t test (WT vs 3a KO p= 0.0083: WT vs 3b KO p= 0.0084; two-sided, n= 3 biologically
independent samples). e DNA methylation status at promoters of representative PcG target genes that exhibited modest derepression upon Dnmt3a
depletion (e.g., Hoxa2 and Pax8). Data from two independent experiments are shown. Each bar indicates a CG site, and bar height represents methylation
percentage (0–100%). Locations of genes and CGIs are indicated below.
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mutant AML (R882: major mutation) relative to DNMT3A WT
AML, suggesting that inactivating DNMT3A mutation causes
defects in epigenetic repression of PcG target developmental
genes (Fig. 6c, d). These results are also consistent with those of a
recent study demonstrating that a gain-of-function mutation at
DNMT3A causes microcephalic dwarfism and hypermethylation
of PcG-regulated genes31. Collectively, these data suggest that the
region specificity of de novo methylation by DNMT3A and
DNMT3B is essentially shared between mice and humans.
Discussion
Although de novo DNA methylation plays a pivotal role during
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precise roles of each DNMT3 enzyme. In this study, we utilized
the hypomethylated ES cells as starting materials in a combina-
tion with genetic disruption of Dnmt3 family methyltransferases,
and successfully unveiled the distinct region-specificity of de novo
methylation activity of these enzymes. Consistent with a previous
report, most regions are similarly methylated in WT, Dnmt3a
KO, and Dnmt3b KO cells after differentiation, indicating the
redundant function of DNMT3A and DNMT3B. However, we
found that DNMT3B has a higher activity of de novo methylation
than DNMT3A, which is remarkably pronounced at CGIs on X
chromosome. In contrast, de novo methylation at PcG target
developmental genes requires DNMT3A, which is different from
the mechanism in the extraembryonic lineage. Furthermore, we
showed that tissue-specific de novo methylation at PcG target
developmental genes is mediated by DNMT3A and is mechan-
istically associated with stable repression of a small subset of the
PcG target genes. Notably, no gene was identified to be hypo-
methylated in Dnmt3a KO epiblasts when compared with WT
epiblasts. Indeed, most of identified DNMT3A target genes are
unmethylated in epiblasts (Supplementary Fig. 9a, b), suggesting
that de novo DNA methylation at these loci occurs after
implantation. Unexpectedly, we found that DNMT3A confers
gene body methylation at PcG target developmental genes, which
is in contrast to other genes being methylated by DNMT3B.
Moreover, we showed that human diseases harboring inactivating
mutations at DNMT3 family genes exhibit reduced methylation at
hypomethylated regions in mouse Dnmt3a and Dnmt3b KO cells.
Here we showed that de novo DNA methylation on the X
chromosome mainly depends on DNMT3B but not on DNMT3A
while de novo methylation at PcG target developmental genes is
mediated by DNMT3A. It should be noted that the inactive X
chromosome is heavily targeted by Polycomb complexes32, sug-
gesting that distinct mechanisms are involved in de novo
methylation at PcG target genes. Notably, more pronounced
reduction in DNA methylation was observed at LINEs in
Dnmt3b KO than Dnmt3a KO 2i-MEFs. Given that greater
occurrence of LINEs on the X chromosome than on autosomes,
the enriched LINEs may account for the preferential reduction in
DNA methylation at the X chromosome in Dnmt3b KO 2i-MEFs.
In summary, taking advantage of DNA-hypomethylated 2i/L
ES cells, we identified a set of unique de novo target sites for DNA
methylation by both DNMT3 enzymes during mammalian
development. Our findings have important implications regard-
ing the roles of de novo methyltransferases in epigenetic regula-
tion of mammalian development and diseases.
Methods
Data reporting. No statistical methods were used to predetermine sample size. No
experiments were randomized. Investigators were not blinded to allocation during
the experiments.
Establishment and culture of ES cells. Zygotes with an F1 genetic background
(129 × 1/SvJ and MSM/Ms) were obtained by in vitro fertilization. S/L ES and 2i/L
ES cells were established in a previous study16. Cells were maintained at 37 °C in an
atmosphere containing 5% CO2. Briefly, S/L ES cells were established and
maintained on feeders (mitomycin C-treated MEFs) in KO DMEM (GIBCO)
containing 2 mM L-glutamine, 100× NEAA, P/S, 15% FBS, 0.11 mM β-
mercaptoethanol (GIBCO), and 1000 U/ml human recombinant LIF (Wako). To
establish S/L ES cells, a blastocyst was placed on feeders in 24-well plates (passage
number 0: p0). After expansion of the ICM, the cells were passaged into 24-well
plates (p1), followed by a second passage into six-well plates (p2) and a third
passage into 6 cm dishes (p3). For derivation of 2i/L ES cells, a blastocyst was
placed on feeders in 24-well plates in KO DMEM containing 2 mM L-glutamine,
100× NEAA, P/S, 15% FBS, 0.11 mM β-mercaptoethanol, 1000 U/ml LIF, 1 μM
PD0325901 (STEMGENT), and 3 μM CHIR99021 (STEMGENT) (p0). After
passage into 24-well plates (p1), the cells were maintained without feeders in
DMEM/F12 (GIBCO) and Neurobasal (GIBCO) supplemented with the B27
(GIBCO) and N2 cell supplement (GIBCO), P/S, 2 mM Glutamax (GIBCO), 1000
U/ml LIF, 1 μM PD0325901, and 3 μM CHIR99021. Cells were passaged into six-
well plates (p2) and expanded into 6-cm dishes (p3).
Genetic deletions of Dnmt3a and Dnmt3b in ES cells. Knockout of Dnmt3a or
Dnmt3b for 2i/L ES cells was performed using CRISPR/Cas916. 2i/L ES cells at p3
were used to establish KO lines. sgRNA sequences were as follows: Dnmt3a,
ACCGCCTCCTGCATGATGCG; Dnmt3b: AATGCACTCCTCATACCCGC.
Establishment of 2i-MEFs by blastocyst injection. Female ICR mice were treated
with pregnant mare serum gonadotropin (PMSG; 7.5 IU) and human chorionic
gonadotropin (hCG; 7.5 IU) by intraperitoneal injection. Embryos were rinsed with
M2 medium (Sigma) and cultured in KSOM medium until development into
blastocysts. WT, Dnmt3a KO, and Dnmt3b KO 2i/L ES cells were trypsinized, and
7–8 cells per embryo were injected into the blastocoels of E3.5 blastocysts. Injected
blastocysts were transferred into the uteri of pseudopregnant ICR mice. A Fully
Automated Fluorescence Stereo Microscope Leica M205 FA (Leica MICRO-
SYSTEMS) was used to observe GFP-labeled embryos. MEFs were isolated from
E14.5 embryos and cultured in DMEM (Nacalai Tesque) with 2 mM L-glutamine
(Nacalai Tesque), 100× nonessential amino acids (NEAA) (Nacalai Tesque), 100 U/
ml penicillin, 100 μg/ml streptomycin (P/S) (Nacalai Tesque), and 10% fetal bovine
serum (FBS) (GIBCO). To remove host cells, GFP-labeled MEFs were collected by
fluorescence activated cell sorting (Aria II, BD) after selection with 350 μg/ml G418
disulfate aqueous solution (Nacalai Tesque) for 7 days.
Establishment of Dnmt3a or Dnmt3l WT and KO MEFs. Dnmt3a WT and KO
embryos were obtained by crossing Dnmt3a heterozygous KO (B6;129S4-Dnmt3a
< tm1Enl>) mice5. Dnmt3l WT and KO embryos were obtained by crossing
Dnmt3l heterozygous KO mice12. MEFs were isolated from E14.5 embryos.
EpiLC induction. Culture medium for EpiLCs induction33 was DMEM/F12+
Neurobasal containing B27 and N2 cell supplements, 20 ng/ml recombinant
human activin A (R&D Systems), 12 ng/ml bFGF (Wako), 100 U/ml penicillin,
100 μg/ml streptomycin, and 1% KO serum replacement (GIBCO).
Animals. All animal studies were conducted in compliance with ethical regulations
in The University of Tokyo and Kyoto University and were approved by Institute
of Medical Sciences, The University of Tokyo and Center for iPS Cell Research and
Application (CiRA), Kyoto University. MSM/Ms were obtained from RIKEN Bio
Resource Center34,35. B6;129S4-Dnmt3a < tm1Enl> mice5 were obtained from
RIKEN Bio Resource Center. C57BL/6, 129×1/SvJ, ICR mice, and pseudopregnant
ICR mice were purchased from SLC. Noon of the day when a plug was observed
was designated as embryonic day (E) 0.5.
Cell lines. All cell lines used for this study were derived in our laboratory and
tested for mycoplasma contamination.
Sex determination. The sex of cell lines and mouse embryos was determined by
PCR using primers for Sry and Uty, both of which are encoded on the Y chro-
mosome. The primers used were as follows: Sry-Fw, CGTGGTGAGAGGCACAA
Fig. 5 Tissue-specific methylation at PcG target genes by DNMT3A. a Schematic of experimental design. Various organs (brain, limb, heart, lung, and
liver) were obtained from Dnmt3aWT and KO embryos at E14.5 for subsequent analyses. b Representative image of Dnmt3aWT and KO embryos at E14.5.
No obvious phenotypic changes were observed in Dnmt3a KO embryos. Scale bars, 10 mm. c CpG methylation levels at the Hoxb cluster in Dnmt3aWT and
KO organs (brain, limb, heart, lung, and liver), as determined by MethylC-seq. Each bar indicates a CpG site, and bar height represents methylation
percentage (0–100%). Locations of genes and CGIs are indicated below. d The left panel shows mean DNA methylation levels at CpG sites within each
representative PcG target gene in various organs, as determined by MethylC-seq. The right panel shows methylation differences between Dnmt3aWT and
KO organs. Color scales indicate DNA methylation levels and their differences, respectively. e DNA methylation status at promoters of Hes7 and Hoxb3.
Each bar indicates a CG site, and bar height represents methylation percentage, as determined by MethylC-seq (0–100%). Locations of genes and CGIs are
indicated below. f Expression levels (FPKM+ 1) of PcG target genes in hearts of Dnmt3a WT and KO embryos, as determined by RNA-seq.
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GTT; Sry-Rv, AGGCAACTGCAGGCTGTAAA; Uty-Fw, GAGTTCTTCTTGCG
TTCACCATCTG; and Uty-Rv, CTATCTAATCCACAAAGCGCCTTCTTC.
GFP labeling of ES cells. ES cells (p3) were labeled by piggyBac transposon car-
rying CAG-EGFP-IRES-Neo36. Plasmid and transposase (2.5 µg each) were trans-
fected into ESCs using Xfect mESC Transfection Reagent (Clontech). Transfected
cells were selected with 350 μg/ml G418 disulfate aqueous solution. GFP positive
colonies were picked and established as GFP-labeled clones (p5).
DNA/RNA extraction and cDNA synthesis. DNA was extracted using the
PureLink Genomic DNA Mini Kit (Invitrogen), and RNA was extracted using the
RNeasy plus Mini Kit (QIAGEN) or NucleoSpin RNA Plus (MACHEREY-
NAGEL). DNA and RNA were quantified on a Nanodrop 2000c (Thermo Fisher
Scientific) and Qubit (Thermo Fisher Scientific). Reverse transcription was per-
formed using the PrimeScript™ II First strand cDNA Synthesis Kit (Takara).
Quantitative RT-PCR. Quantitative PCR was performed using GoTaq qPCR










































































































































































Differentially methylated genes among mouse Dnmt3b target genes (n = 60)  
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system (Applied Biosystems). Transcript levels were normalized against the cor-
responding level of β-actin. Primers used were as follows: Pax8-Fw, ATGCCTCA
CAACTCGATCAGA; Pax8-Rv, ACAATGCGTTGACGTACAACTT; β-Actin-Fw,
GCCAACCGTGAAAAGATGAC; and β-Actin-Rv,
TCCGGAGTCCATCACAATG.
Ezh2 inhibitor (GSK126) treatment. Cells were seeded at a density of 2 × 105 cells
on six-well plates the day before GSK126 treatment. The cells were then cultured in
medium containing 10 μM GSK126 (Funakoshi) for 2 days.
Western blot. Cells were dissolved in 500 μl of RIPA lysis buffer containing
protease inhibitor cocktail (Nacalai Tesque), dithiothreitol (Wako), and phos-
phatase inhibitor cocktail (Nacalai Tesque). For histone extraction, cells were
washed with PBS and treated with trypsin for 5 min. Cells (1 × 106) were lysed with
extraction buffer on ice. The suspension was centrifuged at 12,000 rpm for 10 s, and
the supernatant was removed. Next, 0.2 M H2SO4 was added to the pellet, and the
suspension was then centrifuged at 12,000 rpm for 20 min. The resultant super-
natant was mixed with 100% trichloroacetic acid and centrifuged at 12000 rpm for
20 min; the supernatant was removed. Acetone was added to the pellet and lysed.
The suspension was then centrifuged at 12,000 rpm for 20 min, and the super-
natant was removed. Finally, the pellet was lysed with 1× SDS sample buffer.
Proteins were denatured with 2× SDS at 95 °C for 5 min. A total of 30 μg of
denatured protein was run on a 10% SDS/PAGE gel and transferred to Amersham
Hybond-P PVDF Membrane (GE Healthcare) using PowerPac HC (Bio-Rad).
Membranes were blocked in blocking buffer [1× TBS with 0.05% Tween-20 (TBST)
containing 4% nonfat milk (Nacalai Tesque)], and then incubated overnight at 4 °C
with primary antibodies diluted in blocking buffer. Primary antibodies were as
follows: anti-Dnmt3a (Novus Biological, NB120-13888, 64B1446; dilution, 1:500;
Santa Cruz Biotechnology, sc-20703; dilution, 1:200) and anti-β-actin (Santa Cruz
Biotechnology, sc-47778; dilution, 1:1000). Blots were rinsed with TBST. Mem-
branes were incubated for 90 min at room temperature with HRP-conjugated
secondary antibodies. Secondary antibodies used were ECL Anti-mouse IgG, HRP-
linked whole antibody from sheep (GE Healthcare, NA931V; dilution, 1:5000), and
ECL Anti-rabbit IgG, HRP-linked whole antibody from donkey (GE Healthcare,
NA934V; dilution, 1:5000). After rinsing with TBST, Pierce ECL plus Western
Blotting Substrate (Thermo Scientific) was used for visualization, and bands were
detected on a LAS4000 (GE Healthcare).
Bisulfite sequencing. DNA (200 ng) was bisulfite-treated using the EZ DNA
Methylation-Gold Kit™ (ZYMO RESEARCH). PCR was performed with EX Taq HS
(Takara). PCR products were cloned into pCR4-TOPO vector (Invitrogen). Sub-
cloned colonies were sequenced using M13 reverse primer on an ABI 3500xL
(Applied Biosystems). Primers were as follows: Hoxa1-Fw, AAGTTTGGGG-
TAATTTGGATAAAGG; Hoxa1-Rv, CCAACCCAAAAAAAAACCTAAACTAC;
Zfp467-Fw, AGGTTATTTGTTTGTGTTTAGTGTG; Zfp467-Rv, TCCAAATATA
AATCTCCCAAATCTATC; Meis1-Fw, AGATAGTGAGGGTTTGAAATTTAGT
AAA; and Meis1-Rv, CCACCCCTAACTCCAAATAAAAAT.
Library preparation for whole-genome bisulfite sequencing. DNA (500 ng, as
determined by Qubit) was fragmented by sonication (Covaris) and ligated with
methylated adapters supplied by TruSeq™ DNA, Sample Prep Kit-v2 (Illumina).
Subsequently, DNA was bisulfite-treated using EZ DNA Methylation-Gold Kit™.
Final library amplification was performed using Pfu Turbo Cx (Agilent Technol-
ogies). Sequencing libraries were assessed on a Bioanalyzer (Agilent Technologies)
and quantified using the KAPA Library Quantification Kit (KAPA BIOSYSTEMS).
The libraries were then sequenced on a HiSeq 2500 (Illumina) as 2× 100 bp or 2×
101 bp paired-end reads.
Library preparation for target-captured bisulfite sequencing. DNA (3 μg, as
determined by Qubit) was fragmented by sonication. Subsequently, library pre-
paration was performed using the SureSelectXT Mouse Methyl-Seq Reagent Kit
(Agilent Technologies). The Methyl-Seq Kit could enrich 109Mb of mouse
genomic regions including CpG islands, Gencode promoters, DNase I hypersen-
sitive sites, and tissue-specific DMRs. DNA was bisulfite-treated using the EZ DNA
Methylation-Gold Kit™. Sequencing libraries were assessed by Bioanalyzer and
quantified using the KAPA Library Quantification Kit. The libraries were
then sequenced on a HiSeq 2500 (Illumina) as 2× 100 bp or 2× 101 bp paired-
end reads.
Library preparation for RNA sequencing. RNA (200 ng) was prepared for library
construction. High-quality RNA (RNA Integrity Number value ≥8, as determined
by Bioanalyzer) was used for library preparation. RNA-seq libraries were generated
using the TruSeq Stranded mRNA LT sample prep kit (Illumina). PolyA-
containing mRNA was purified by magnetic beads conjugated to poly-T oligos, and
RNA was fragmented and primed for cDNA synthesis. Cleaved RNA fragments
were reverse transcribed into first-strand cDNA using transcriptase and random
primers. Second-strand cDNA was synthesized by incorporation of dUTP, and ds
cDNA was separated using AMPure XP beads (Beckman Coulter). A single “A”
nucleotide was added to the 3′ ends of the blunt fragments, and adapters with index
were ligated to the ends of ds cDNAs. ds cDNA fragments were amplified by PCR
using PCR primer Cocktail (Illumina). The number of PCR cycles was minimized
(11–15 cycles) to avoid skewing the representation of the libraries. RNA-seq
libraries were sequenced on a NextSeq500 (Illumina) as 75 bp single reads.
DNA methylation data analyses. For WGBS and MethylC-seq analyses of 129/
MSM genetic background cells and tissues, SNP data for MSM/Ms were obtained
from the NIG Mouse Genome Database (MSMv4HQ, http://molossinus.lab.nig.ac.
jp/msmdb/index.jsp), and the MSM/Ms mouse genome was reconstructed from
mm10 using these SNPs. Information about indels was not used in this study. Bases
with low-quality scores and the adapters in all sequenced reads were trimmed with
cutadapt-1.1437. Trimmed reads were mapped independently to both the B6
(mm10) and MSM/Ms mouse genomes using the Bismark software-v0.18.238 with
bowtie2 (version 2.3.0)39. Reads uniquely mapped to the same chromosome and
positions of both B6 and MSM/Ms genomes were used for further analyses. B6
(129)-derived and MSM/Ms-derived sequenced reads were determined based on
MSM/Ms SNP data. The Y chromosome and mitochondrial genome were omitted
from the MSM/Ms reference genome due to the lack of SNP data. SNPs in CpG
sites were excluded, and the patterns of bisulfite conversion were taken into
account in the determination of parental alleles. Methylated cytosines were
extracted from reads using the Bismark methylation extractor with the following
options:–ignore 10–ignore_r2 10–ignore_3prime 5–ignore_3prime_r2 5. For
MethylC-seq analysis of B6 genetic background tissues, trimmed reads were
mapped to the mouse genome (mm10) using Bismark software-v0.18.2 with
bowtie2 (version 2.3.0) and default settings, and uniquely mapped reads were used
for extraction of methylated cytosines using the Bismark methylation extractor
with options–ignore 10–ignore_3prime 5 (single-end reads) or–ignore
10–ignore_r2 10–ignore_3prime 5–ignore_3prime_r2 5. For MethylC-seq analysis,
because probe sequences of the SureSelectXT were designed for the original top
strand, only the original bottom data were used for this analysis. The Integrative
Genomics Viewer (version 2.8.2)40 was used to visualize CpG methylated
status (CpG sites at ≥5× coverage). Genomic locations for each genetic element
were described previously41. UCSC LiftOver42 (http://genome.ucsc.edu/) was
used to convert the coordinates of the mm9 assembly to those of the mm10
assembly.
Identification of differentially methylated loci and regions. The R/Bioconductor
package DSS43 was used to identify differentially methylated loci and regions. For
identification of epiblast-specific methylated loci (Fig. 1b), the DMLtest function in
Fig. 6 Reduced DNA methylation in patients with DNMT3 mutations. a Heatmap of DNA methylation levels at differentially methylated genes in mouse
DNMT3B target genes in ICF syndrome patients-derived B cell lines [DNMT3B wildtype (WT): two patients, DNMT3B mutant (Mut): two patients], as
determined by reduced representation bisulfite sequencing (RRBS). Genes differentially methylated (|WT-Mut| >= 0.1) between WT and DNMT3BMut are
shown (n= 60). Note that most of differentially methylated genes (n= 57) exhibited reduced DNA methylation in DNMT3B-mutated ICF patients. DNA
methylation datasets were obtained from GSE9574749. b DNA methylation status at representative loci of mouse DNMT3B target genes in ICF patients.
DNMT3B target genes in mice were hypomethylated similarly in DNMT3B-mutated ICF patients. Each bar indicates a CG site, and bar height represents
methylation percentage, as determined by RRBS (0–100%). Locations of genes are indicated below. c Heatmap of DNA methylation levels at PcG target
developmental genes of 68 AML patients [DNMT3A wildtype (WT): 54 patients, DNMT3A mutant (Mut): 14 patients] by Infinium assay obtained from
GSE6229829. Thirty PcG target genes whose average methylation levels within gene bodies differed (p < 0.05; two-sided, Mann–Whitney U-test) between
DNMT3A WT (white) and DNMT3A Mut (gray) are shown. Color scale indicates DNA methylation levels. d Box plots of DNA methylation levels within
gene bodies of HOXA6, HOXB3, and MEIS1 in DNMT3A WT (54 patients) and DNMT3A Mut (14 patients) AML. Bold black lines indicate the median
methylation levels. The bottom and top of the box are lower and upper quartiles, respectively. Whiskers extend to ±1.5 IQR. (HOXA6, p= 0.0006: HOXB3,
p= 0.0325: MEIS1, p= 0.0166; two-sided, Wilcoxon signed-rank test).
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the DSS package (FDR < 0.05, Epi > ICM) was used with WGBS data (CpG sites at
≥5× coverage) obtained from GSE84236 to determine significantly differentially
methylated loci. For identification of DNMT3A and DNMT3B target regions
globally (Fig. 2a and Supplementary Data 2), the DMLtest function in the DSS
package (FDR < 0.01 and difference in methylation levels (WT–KO) > 0.4) was
used with 1k tiled CpG methylation WGBS data (CpG sites at ≥10× coverage) to
determine significantly differentially methylated tiles (DMTs; Supplementary
Data 1). For identification of DNMT3A and DNMT3B target genes (Fig. 2b, c,
Supplementary Fig. 3a, b and Supplementary Data 1–5), the DMLtest and callDMR
functions in the DSS package (delta= 0.2, p.threshold= 0.00001, minCG= 10)
were used with MethylC-seq data (CpG sites at ≥50× coverage) to determine
significantly differentially methylated regions (DMRs, each KO vs WT, Supple-
mentary Data 2 and 4). The genes included in the DMRs (WT > KO) were defined
as target genes (Supplementary Data 3 and 5). Gene locations were obtained from
the GENCODE annotation file (vM15).
RNA-seq data analyses. After trimming of adaptor sequences and low-quality
bases with cutadapt-1.1537, sequenced reads were mapped to the mouse reference
genome (mm10) using tophat-2.1.144 with the GENCODE version M15 annota-
tion.gtf file and the aligner Bowtie2-2.3.239. Uniquely mapped reads (MAPQ ≥ 20)
were used for further analyses. The expression level of each gene was calculated as
fragments per kilobase per million mapped reads (FPKM) using cufflinks-2.2.145.
ChIP-seq data analysis. Raw ChIP-seq data (Dnmt3a and Dnmt3b binding data)
in ES cells were obtained from GSE5741314. Adaptors and low-quality bases at the
3′ ends of reads were trimmed using cutadapt-1.1537. Untrimmed and trimmed
reads of 20 bp or more were mapped to the mouse genome (mm10) with BWA
0.7.1246. Duplicate reads, chimeric reads, and reads with low mapping quality
(MAPQ < 20) were removed using Picard (http://broadinstitute.github.io/picard/)
and SAMtools47. Reads mapped to blacklisted regions (https://sites.google.com/
site/anshulkundaje/projects/blacklists) were excluded from further analysis. Aver-
age ChIP-seq plots were drawn using ngsplot-2.4748.
Reporting summary. Further information on research design is available in
the Nature Research Life Sciences Reporting Summary linked to this article.
Data availability
All data analyzed by WGBS, MethylC-seq, and RNA-seq were deposited in the Gene
Expression Omnibus (GEO) under accession number GSE111172. MethylC-seq data
from Dnmt3a WT tissue were deposited under accession number GSE111173. The
publicly available datasets used in this study are: GSE84236, GSE95747, GSE62298,
GSE57413, GSE96529, GSE95747, GSE62298. All other relevant data supporting the key
findings of this study are available within the article and its Supplementary Information
files or from the corresponding authors upon reasonable request. The source data
underlying Supplementary Fig 4c are provided as a Source Data file. A reporting
summary for this Article is available as a Supplementary Information file.
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